CIA
AMPH icon

Concurrent Investment Advisors’s Amphastar Pharmaceuticals AMPH Stock Holding History

Concurrent Investment Advisors’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,778
Closed -$693K – 993
2024
Q1 		$693K Buy
+15,778
New +$815K 0.03% 462

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concurrent Investment Advisors's AMPH Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2024, closing a stake of 15,778 shares — an estimated $693K sold.

Concurrent Investment Advisors first reported a position in AMPH in Q1 2024 and held it in 1 quarter. The position peaked at $693K in Q1 2024. 269 funds tracked by Wall St. Rank hold AMPH as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining Amphastar Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 15,778 Amphastar Pharmaceuticals shares in Q2 2024, an estimated $693K.
  • Concurrent Investment Advisors first reported a position in Amphastar Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Concurrent Investment Advisors's Amphastar Pharmaceuticals position peaked at $693K in Q1 2024.
  • 269 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.